ESCRS - PP23.08 - Rocklatan Could Raise Hopes For Glaucoma Patients.

Rocklatan Could Raise Hopes For Glaucoma Patients.

Published 2023 - 41st Congress of the ESCRS

Reference: PP23.08 | DOI: 10.82333/pwx5-9a73

Authors: Mina Abdelmseih* 1

1Ophthalmology Department , Augen AMVZ,Hoyerswerda,Germany

To assess the effectiveness of ROCKLATAN, a topical therapy comprising netarsudil and latanoprost ophthalmic solution 0.02%/0.005%, in patients with open-angle glaucoma and ocular hypertension

Ophthalmology Department in Augen MVZ, Germany

Two randomized and controlled clinical trials were conducted to evaluate the effectiveness of ROCKLATAN (a solution containing netarsudil and latanoprost for ophthalmic use) with a concentration of 0.02%/0.005%.

The results showed that ROCKLATAN was superior to either netarsudil or latanoprost alone in reducing intraocular pressure (IOP). After three months of treatment, 58.4% of patients on ROCKLATAN achieved an IOP of 16 mmHg or lower compared to 37.3% of patients on latanoprost alone. Additionally, 30.9% of patients on ROCKLATAN achieved at least a 40% reduction in mean diurnal IOP compared to 5.9% on netarsudil alone and 8.5% on latanoprost alone. These results were maintained over the 12-month study period.

ROCKLATAN with once-daily dosing, has shown to be more effective than using either netarsudil or latanoprost alone. This combination has the potential to decrease the treatment burden and improve adherence and clinical outcomes for patients with open-angle glaucoma or ocular hypertension.